YOLFTbeta
Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

DMRA · NASDAQ · Healthcare / Biotechnology

21.60USD-0.45 (-2.04%)

Price History

Full chart

Market Stats

Previous Close22.05
Open22.11
Day Range21.10 – 22.39
52-Week Range3.50 – 38.33
Volume475.27K
Market Cap1.25B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.26
Dividend Yield0.00%
Beta1.47
50-Day Avg28.65
200-Day Avg26.38

About

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Jennifer A. Jarrett M.B.A.
  • Employees7
  • HeadquartersBuilding 23, Waltham, MA, United States, 02453, USA
  • Websitehttps://www.damoratx.com

Leadership

  • Mr. Garrett Winslow Esq.Senior VP, General Counsel & Corporate Secretary · b. 1979
  • Ms. Jennifer A. Jarrett M.B.A.CEO, President & Director · b. 1971
  • Mr. Ulf J. Nilsson Ph.D.Co-Founder
  • Dr. Hakon Leffler M.D., Ph.D.Co-Founder
  • Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.Co-Founder
  • Mr. Brian Burkavage CPASenior VP of Finance, Principal Financial & Accounting Officer · b. 1983
  • Mr. Sherwin SattarzadehChief Operating Officer · b. 1979
  • Dr. Becker Hewes M.D.Chief Medical Officer · b. 1966

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---00000
Cost of Revenue-111.00K188.00K441.00K490.00K830.00K181.00K34.00K
Gross Profit--111.00K-188.00K-441.00K-490.00K-830.00K-181.00K-34.00K
Operating Expense-38.86M33.45M51.79M60.72M35.63M16.72M210.84M
Operating Income-12.91M-38.97M-33.64M-52.23M-61.21M-36.46M-16.90M-210.87M
EBITDA-12.91M-38.86M-33.45M-51.31M-61.13M-37.52M-21.22M-209.75M
Net Income-15.87M-36.51M-34.84M-51.75M-61.62M-38.35M-21.44M-209.84M
R&D10.09M36.53M24.63M38.49M48.21M23.77M6.40M201.19M
Interest Expense2.97M-------

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets35.10M56.61M171.60M122.22M73.19M38.23M17.13M260.53M
Total Liabilities4.44M8.14M6.11M4.99M11.44M5.90M2.66M20.15M
Total Equity30.66M48.47M165.49M117.22M61.75M32.33M14.47M240.38M
Cash30.99M11.29M163.58M62.56M32.79M21.46M14.18M257.62M
Total Debt-298.00K915.00K847.00K804.00K249.00K1.43M68.00K
Net Debt-30.99M-11.00M-162.67M-61.72M-31.98M-21.22M-12.74M-257.56M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-13.69M-19.33M-38.20M-52.31M-42.93M-36.91M-18.62M-6.73M
Investing Cash Flow--326.00K--48.05M12.38M22.33M11.65M-17.37M
Financing Cash Flow42.87M-187.39M0507.00K2.88M0266.84M
Capital Expenditure000223.00K196.00K000
Free Cash Flow-13.69M-19.33M-38.20M-52.53M-43.13M-36.91M-18.62M-6.73M
FCF to OCF100.00%100.00%100.00%100.43%100.46%100.00%100.00%100.00%

Earnings

Report DateDec 11, 2020Mar 29, 2021May 4, 2021Aug 5, 2021Nov 4, 2021Feb 17, 2022Apr 29, 2022Jul 29, 2022Nov 8, 2022Mar 9, 2023Apr 28, 2023Jul 31, 2023Nov 6, 2023Mar 25, 2024Apr 29, 2024Aug 12, 2024Nov 1, 2024Mar 19, 2025May 9, 2025Aug 6, 2025Nov 7, 2025Mar 20, 2026May 13, 2026Aug 10, 2026Nov 5, 2026
EPS Estimate-502.75--11.50-13.50-14.00-14.00--17.25-17.00-14.25--14.67-12.12--4.25-6.00-3.70-3.12----0.11-0.65-0.38-0.52
EPS Actual-1381.25-3.89-13.25-12.25-12.50-13.25-16.76-16.75-13.50-13.75-12.65-10.25-4.99-5.97-5.00-5.00-3.39-5.22-1.92-2.60-2.362.31-0.81-0.39-
Surprise-174.74%--15.22%9.26%10.71%5.36%-2.90%20.59%3.51%-30.13%58.83%--17.65%16.67%8.38%-67.31%---2236.89%-24.62%-2.63%-
TimingPre-market-Pre-marketPre-marketAfter-hoursAfter-hours-Pre-marketPre-marketPre-market-After-hoursAfter-hours-After-hoursAfter-hoursPre-marketAfter-hours-----After-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.25B
Enterprise Value1.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.27
EPS-0.26
Book Value6.25
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-96.33M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-99.74%
Return on Assets-21.61%
Shares Outstanding61.74M
Shares Float41.40M
Beta1.47
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
105.75%
Insiders
8.41%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    9.05M14.65%
  • Fairmount Funds Management LLC
    8.71M14.11%
  • venBio Select Advisor LLC
    3.78M6.13%
  • VR Adviser, LLC
    3.60M5.84%
  • FCPM III SERVICES BV
    2.44M3.95%
  • RA Capital Management, LLC
    2.40M3.89%
  • HHG PLC
    2.36M3.83%
  • Viking Global Investors LP
    2.31M3.74%
  • Bellevue Group AG
    2.30M3.72%
  • Remedium Capital Partners, LLC
    2.05M3.31%
  • COMMODORE CAPITAL LP
    1.94M3.14%
  • Cormorant Asset Management, LLC
    1.52M2.47%
  • Balyasny Asset Management LLC
    1.45M2.35%
  • Perceptive Advisors LLC
    1.22M1.98%
  • Point72 Asset Management, L.P.
    1.19M1.93%
  • Wellington Management Company LLP
    1.06M1.71%
  • Siren, L.L.C.
    900.00K1.46%
  • BRAIDWELL LP
    894.85K1.45%

Top Fund Holders

  • Fidelity Growth Company Fund
    1.83M2.96%
  • iShares Russell 2000 ETF
    1.34M2.18%

Stock Splits

  • Aug 30, 20241:25